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Abstract
Heart failure is a growing disease that affects millions of people around the 
world. Heart transplantation is currently the therapy of choice for these patients. 
However, the lack of donors has forced the physician to evolve another kind of 
therapy such as ventricular assist device (VAD) as a bridge to transplant to com-
pensate the lack of organs. Ventricular assist devices are today a successful therapy 
for the treatment of heart failure; the evolution of these devices and their progres-
sive miniaturization have allowed an evolution of their implantation technique. 
To date, therefore, in addition to the traditional implant through sternotomy, 
there are more mini-invasive implant techniques. The purpose of the treaty is to 
describe these techniques, the implantation sites, and the benefits they can bring 
to patients.
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1. Introduction
Heart failure is a chronic progressive disease characterized by decreased 
pump function. This may lead to venous congestion and also to hypoperfusion 
due to low cardiac output with severe organ comorbidities. Modern conserva-
tive therapies for heart failure have improved outcomes in adult patients [1]. 
Despite medical advances in treating this condition, the disease itself remains a 
progressive condition. For treating end-stage heart failure, cardiac transplanta-
tion remains the gold standard. Despite this evidence, cardiac transplantation as 
a therapeutic option is limited by donor organ shortage and is therefore limited 
to patients younger than 65 years [2]. However a promising alternative to cardiac 
transplantation is ventricular assist device (VAD) implantation. In consideration 
of these problems, the number of VAD implantations has exceeded the number of 
cardiac transplantations [3]. This therapeutic trend, i.e., the increasing number of 
patients who undergo VAD implantation also as a destination therapy (DT), has 
led to an obvious longer duration of the assistance period with the cardiovascular 
assistance system. This has also led to a change in the basal characteristics of 
patients who (especially DT patients) are increasingly older, are more fragile, have 
greater comorbidities, and, consequently, may have a higher incidence of surgical 
complications [4]. For several years the choice approach for VAD implantation was 
sternotomy. However, destination therapy patients suffered a greater intraopera-
tive risk and increased mortality [5]. Nonetheless, Slaughter showed that treatment 
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with VADs significantly increased survival of DT patients. At that time the ster-
notomy approach was mandatory due to the size of the VADs [6]. Technological 
progress has allowed a miniaturization of the devices and their better hemody-
namic performance. This has allowed the development of mini-invasive implant 
techniques that allow a lower surgical risk for patients, less trauma, less incidence 
of bleeding, and obviously less patient stay in intensive therapy [7]. The purpose 
of this chapter is to describe the mini-invasive VAD implantation techniques and 
to describe the possible benefits that these techniques can bring to the patient’s 
outcome.
2. Indication and standard approach
The indications for the implantation of left ventricular device mainly concern 
patients suffering from left ventricular failure with ejection fraction ≤25% and 
a preserved right ventricular function (Table 1 summarizes the main indica-
tions as indicated by the European guidelines on heart failure 2016) [8]. The 
standard approach for left ventricular assist device (LVAD) implantation is full 
sternotomy; it is done as the “first choice” in many centers around the world 
based on the long-term experience. The advantages of this approach are various: 
certainly full sternotomy provides the best anatomical overview of the heart and 
the major vessel and structures; moreover full sternotomy allows to approach dif-
ferent procedures that can be correlated and necessary to the LVAD implantation 
such as closure of septal defects, repair of the tricuspid valve, or ligation of the 
left atrium due to atrial fibrillation [9]. The classical implant operation through 
median sternotomy also involves the use of the heart-lung machine; the operation 
is divided into three main steps:
1. Connection between the left ventricle (LV) and inflow cannula.
2. Tunneling of the driveline.
3. Anastomosis of the outflow cannula to the ascending aorta.
The cannulation sites to establish the heart-lung machine are classically the right 
atrium and ascending aorta. The main advantages in using the heart-lung machine 
are two: the first one is the possibility to view and resect the trabeculae that could 
later cause blood turbulence and thrombus formation; the second one is the possibil-
ity to do intraoperative ventricular inspection if there’s echocardiography evidence 
of left ventricle thrombus. However the standard surgical approach has several 
disadvantages: sternotomy causes pericardial adhesions and possible dangerous 
conditions in case of reoperations (e.g., in case of transplantation in BTT patients 
or in the case of pump exchange). Moreover, sternotomy leads to greater risk of 
postoperative bleeding, sternal infections, and wound dehiscences and therefore 
increases the patient’s surgical trauma and risk of secondary right heart failure [7].
As previously mentioned traditionally, the implantation of the LVAD is per-
formed with the help of the heart-lung machine. It is known, however, that this 
machine plays an important role in the activation of inflammatory mediators, 
increased pulmonary vascular resistance, platelet activation, coagulopathy, and 
impaired renal function [10]. The patient population that requires VAD implanta-
tion often has evidence of end-organ dysfunction, including liver congestion, renal 
insufficiency, and pulmonary edema. VAD placement under cardiopulmonary 
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bypass (CPB) often exacerbates these pre-existing conditions, resulting in 
postoperative coagulopathy, bleeding, and worsening right heart failure. VAD 
implantation without the use of CPB could help to minimize these postoperative 
complications [11].
3. Minimally invasive LVAD implantation (off-pump technique)
Minimally invasive implantation techniques require patient assessment and 
evaluation. Echocardiography helps identify patients with valvular disease who 
need concomitant valve procedure and would preferably be approached through a 
standard midline sternotomy. In the presence of left ventricle thrombus, an on-
pump approach should be performed for thrombus removal. Noncontrast chest 
computed tomography is helpful in determining which intercostal space to be used 
and whether an anterolateral or lateral mini-thoracotomy should be utilized (most 
of the time, fifth or sixth intercostal space). Chest computed tomography will also 
be useful for the evaluation of the outflow aortic anastomosis site and to rule out 
aortic calcification and aneurysm [12].
The LVAD implantation is divided into three steps:
1. Inflow cannula and pump insertion.
2. Outflow graft (OG) insertion.
3. Driveline insertion.
The minimally invasive implantation procedure could be done for the first 
two steps.
Table 1. 
Indication for implantation of LVAD.
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4.  Minimally invasive implantation of inflow cannula and pump 
insertion
There are two types of minimally invasive approaches to implant the VAD and 
the inflow cannula; the first one we describe is a left subcostal incision (Figure 1). 
This kind of approach was used mainly for the LVAD HeartMate II that is the largest 
of the contemporary LVAD devices [13]. A subcostal incision is used, running 
along the left-sided rib cage. After division of the abdominal muscles, preparation 
anteriorly to the diaphragm is performed. Through this access, the pericardium can 
be divided and the left ventricular apex easily identified [14].
The second one is via left anterior thoracotomy at the fifth or sixth intercostal 
space (Figure 2). Intraoperative echocardiography is used to identify the LV 
apex location and to determine the optimal location and intercostal space for left 
thoracotomy. A 6 cm thoracotomy incision is usually performed in the fifth or 
sixth intercostal space; upon entering the chest, the pericardium is identified and 
divided, and a pericardial cradle is created with pericardial sutures to expose the LV 
apex [12].
In case of an off-pump VAD placement, there are techniques that can be used to 
reduce the use of blood. Reliant on the experience in transcatheter valve implanta-
tion by the use of rapid pacing, multiple authors reported inserting off-pump 
LVAD with rapid pacing for the insertion [15]. Implantation of LVAD with non-
fibrillatory technique by administrating of an intravenous bolus of adenosine 
to induce a short bradycardic arrest during off-pump LVAD placement was also 
described [16], in order to reduce blood loss by reducing both the volume of the 
blood ejected from the heart during LVAD implant (reduction in blood pressure) 
and decreasing the heartbeats. In this method adenosine mediates pulmonary 
vasodilatation, which may reduce pulmonary resistance and protect the right 
ventricle function [17].
Figure 1. 
Left subcostal incision.
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5. Outflow graft insertion
This step of LVAD implantation technique could be done by multiple ways in 
different locations: right mini-thoracotomy, split upper hemi-sternotomy, axil-
lary and subclavian arteries, supraceliac abdominal aorta, innominate artery, and 
descending aorta [18].
The most commonly used technique for on-pump minimally invasive strategy 
of LVAD implantation is through upper hemi-sternotomy (Figure 3) [19]. A 4 cm 
upper hemi-sternotomy is performed to expose the ascending aorta; if CPB is 
planned, the distal ascending aorta could be used for arterial cannulation to assure 
adequate cerebral perfusion, and femoral vein is used for a percutaneous venous 
cannulation. It can be associated with either inflow pump incisions; for the majority 
of patients, the outflow graft is tunneled and passed within the pericardium and 
anastomosed to the proximal ascending aorta (Figure 4). The OG could be passed 
in the anterior mediastinum behind the sternum in case of previous sternotomy.
Another way to implant the OG is through right mini-thoracotomy (Figure 5). 
This kind of approach can be used if the ascending aorta demonstrated a right-side 
curvature on preoperative chest tomography. A 4–6 cm incision is made at second 
to third intercostal spaces which allows access to the ascending aorta to perform the 
outflow anastomosis: after passing the outflow graft from the left thoracotomy to 
the right thoracotomy, a side-biting clamp is attached on the ascending aorta, and 
after adequate incision of the aorta, the graft is anastomosed in the usual manner. 
Another method is the combination of the previous two approaches through an 
upper hemi-sternotomy with right hemi-thoracotomy J-shape incision (Figure 6). 
At least left subclavian outflow graft anastomosis has been increasingly utilized for 
patient’s anatomy when OG anastomosis to the ascending or the descending aorta is 
prohibited (Figure 7). The OG is tunneled through the right or the left pleural cavity 
and passed through the second intercostal space to be anastomosed to the subclavian 
artery (Figure 8). If this technique is used, attention must be paid to the eventual 
Figure 2. 
Left anterior thoracotomy at fifth or sixth intercostal space.
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compression of the OG by adjacent structures; it is necessary to reduce the possibil-
ity of creating excess flow to the arm and also the turbulence of the flow in case of 
mobilization of the arm. Banding of the subclavian artery is mandatory if there is a 
mean pressure difference of more than 20 mmHg to avoid excessive blood flow to the 
arm [20].
Two further types of approaches are used less frequently: single left thora-
cotomy incision with descending aorta anastomosis (Figure 9) and supraceliac 
Figure 3. 
Upper hemi-sternotomy.
Figure 4. 
The OG anastomosed to the proximal ascending aorta.
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abdominal aorta anastomosis (Figure 10). In the first approach, the inferior 
pulmonary ligament is freed to optimize exposure; the OG is placed in the left 
pulmonary fissure, measured, and anastomosed end to side to the descend-
ing aorta or the aortic arch using a partial cross clamp [21]. The second one is 
used by making left subcostal incision and dividing the diaphragm to make the 
pocket. This allows the LVAD to be implanted on the diaphragmatic surface of 
Figure 5. 
Right hemi-thoracotomy.
Figure 6. 
Right hemi-sternotomy J-shape incision.
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the left ventricle, and the supraceliac aorta is then exposed by extraperitoneal 
exposure. The outflow is trimmed and anastomosed end to side on the supraceliac 
aorta [22].
Figure 7. 
Left hemi-thoracotomy.
Figure 8. 
The OG anastomosed to the subclavian artery.
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6. Conclusions
The use of LVAD has increased significantly along with the rapidly expanding 
heart failure patient population. Like in other cardiac surgical procedures, mini-
mally invasive approaches are becoming more commonly used, also in the field of 
VAD implantation. Multiple studies have shown minimally invasive cardiac surgery 
improves outcomes with reduced surgical trauma and complication rates, e.g., post-
operative bleeding, reduced blood transfusion requirement, faster recovery rate, and 
Figure 9. 
Single left thoracotomy incision with descending aorta anastomosis.
Figure 10. 
Supraceliac abdominal aorta anastomosis.
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decreased hospital cost. However it remains a matter of debate if these approaches 
offer advantages in comparison to standard full-sternotomy access in LVAD implanta-
tion procedure. An undeniable advantage of the minimally invasive implantation 
technique is the lack of adhesions at the time of transplant, which facilitates heart 
transplantation and also reduces ischemia time resulting in improved graft perfor-
mance. The use of off-pump LVAD implantation approach allows the avoidance of 
cardiopulmonary bypass and will decrease the incidence of vasoplegia and coagulop-
athy postoperatively. Another advantage of a less invasive approach is that the right 
ventricle remains in its natural position, as the surrounding pericardium stays intact 
and the right ventricular function remains sustained; in this way right ventricular fail-
ure is passively avoided [23]. The progressive miniaturization of VADs has provided 
a further boost to the research of mini-invasive implantation techniques, and future 
research will tend towards ever greater device miniaturization. LVAD implantation 
by minimally invasive procedure is feasible and safe; LVAD implantation without the 
use of CPB has the potential to minimize postoperative complication such as excessive 
bleeding during implantation without compromising hemodynamics. By minimizing 
the needs for blood transfusions, patients have decreased exposure to blood antigens 
which ultimately reduces the risk of sensitization in BT patients. The upcoming 
advancement of LVAD technology and miniaturization of mechanical circulatory 
support will only further advance the success of LVAD surgery and will benefit more 
patients especially with the rapidly growing heart failure population worldwide.
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